Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 18;14(1):19122.
doi: 10.1038/s41598-024-69926-y.

Association of fibrotic markers with diastolic function after STEMI

Lawien Al Ali  1 , Wouter C Meijers  2   3 , Iris E Beldhuis  2 , Hilde E Groot  2 , Erik Lipsic  2 , Dirk J van Veldhuisen  2 , Adriaan A Voors  2 , Iwan C C van der Horst  4 , Rudolf A de Boer  2   3 , Pim van der Harst  5
Affiliations

Association of fibrotic markers with diastolic function after STEMI

Lawien Al Ali et al. Sci Rep. .

Abstract

Galectin-3 and Suppression of tumorigenicity-2 (ST2) are known markers of cardiac fibrosis. We investigated the prognostic value of fibrotic markers for the development of diastolic dysfunction and long-term outcome in patients suffering an ST-elevated myocardial infarction (STEMI). We analyzed 236 patients from the GIPS-III cohort with available echocardiographic studies and plasma measurements at hospitalization and after 4 months follow-up. Adjusted logistic mixed effects modelling revealed no association between the occurrence of diastolic dysfunction over time with abnormal plasma levels of galectin-3 and ST2. We observed no differences regarding survival outcome at follow-up of 5 years between patients with normal versus abnormal values in both galectin-3 (P = 0.75), and ST2 (P = 0.85). In conclusion, galectin-3 and sST2 were not associated with the development of diastolic dysfunction in non-diabetic patients that presented with a STEMI.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Prevalence of diastolic dysfunction over time.
Figure 2
Figure 2
Biomarker levels over time. Median levels of serum galectin-3 (A) and serum sST2 (B) after acute STEMI, at hospitalization and after 4 months, are shown. Whiskers represent interquartile ranges.
Figure 3
Figure 3
Association of diastolic dysfunction over time with elevated plasma levels of galectin-3 at hospitalization (A), 4 months follow-up (B), and categorical change between hospitalization and 4 months follow-up (C).
Figure 4
Figure 4
Association of diastolic dysfunction over time with elevated plasma levels of sST2 at hospitalization (A), 4 months follow-up (B), and categorical change between hospitalization and 4 months follow-up (C).
See this image and copyright information in PMC

References

    1. Talman, V. & Ruskoaho, H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res.365, 563–581 (2016). 10.1007/s00441-016-2431-9 - DOI - PMC - PubMed
    1. Kakkar, R. & Lee, R. T. The IL-33/ST2 pathway: Therapeutic target and novel biomarker. Nat. Rev. Drug Discov.7, 827–840 (2008). 10.1038/nrd2660 - DOI - PMC - PubMed
    1. Weinberg, E. O. et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation107, 721–726 (2003). 10.1161/01.CIR.0000047274.66749.FE - DOI - PubMed
    1. Liu, F. T. et al. Expression and function of galectin-3, a β-galactoside-binding lectin, in human monocytes and macrophages. Am. J. Pathol.147, 1016–1028 (1995). - PMC - PubMed
    1. Sharma, U. C. et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation110, 3121–3128 (2004). 10.1161/01.CIR.0000147181.65298.4D - DOI - PubMed

Grants and funding

LinkOut - more resources